Topic: neurodegenerative diseases
Preclinical studies suggest sGC stimulator IW-6463 can improve dendritic spine density, reduce neuroinflammation and increase brain blood flow.
Biogen is keeping mum about its plans, stating only that it is preparing modules of the common technical document for submission to the FDA.
In roundworm models of Parkinson's, probiotic Bacillus subtilis lowered the buildup of alpha-synuclein in the brain—a culprit in the disease.
The CK1 inhibitor passed tests in healthy volunteers at Pfizer before getting derailed by the Big Pharma’s retreat from neuroscience R&D in 2018.
In mouse models of ALS, a one-time injection of a short RNA in the spinal cord either prevented the onset of the disease or halted its progression.
Looks like Biogen is going all in on Alzheimer’s disease—the Big Biotech is picking up a tau-targeting treatment from Ionis for $45 million upfront.
The retreat of big biopharma from neuroscience R&D continued apace in 2019, with Amgen axing its neuroscience unit and Eli Lilly shuttering a U.K. fac
Parkinson's patients in a trial of Novartis' Tasigna showed a boost in dopamine that may have halted the decline of motor and non-motor functions.
Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.
A cell therapy for Parkinson’s disease starts out simple, but quickly gets complicated with the potential for immune responses and cancer mutations.